Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 5/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 4/20 | 0.37 |
| ▸ | CA1 | P00915 | 4/20 | 0.37 |
| ▸ | CA2 | P00918 | 4/20 | 0.37 |
| ▸ | CA9 | Q16790 | 4/20 | 0.37 |
| ▸ | F2R | P25116 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6529957 | 0.83 | PARP1 (0.37) | PDE3BPDE3A | |
| SCHEMBL6508991 | 0.82 | PARP1 (0.44) | — | |
| SCHEMBL27032631 | 0.81 | ATR (0.47) | ATRBRD4CA12CA1CA2 | |
| SCHEMBL6510968 | 0.75 | DRD1 (0.33) | — | |
| SCHEMBL30803398 | 0.74 | ATR (0.42) | ATRBRD4 | |
| SCHEMBL6511907 | 0.74 | ATR (0.42) | ATRBRD4DYRK1A | |
| SCHEMBL6509041 | 0.74 | ATR (0.42) | ATRBRD4DYRK1AATRIP | |
| SCHEMBL6509760 | 0.74 | ATR (0.42) | ATRBRD4DYRK1AATRIP | |
| SCHEMBL6508889 | 0.74 | ATR (0.42) | ATRBRD4DYRK1A | |
| SCHEMBL6511027 | 0.74 | ATR (0.42) | ATRBRD4DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | ATR 717/4885BRD4 874/4885CA12 4451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.